title: Achievement of pregnancy three times in the same patient during luteal GnRH agonist administration.
abstract: Gonadotrophin-releasing hormone agonist (GnRHa) administration from the mid-luteal phase onwards is considered the gold standard of ovarian stimulation for IVF treatment. It might, however, coincide with an implanting spontaneous pregnancy. Concerns have therefore been raised with regard to the evolution of the resulting pregnancies and long-term outcome of the children born. The current case report describes the achievement of three pregnancies in the same patient during luteal administration of GnRHa. One pregnancy ended in spontaneous abortion and the other two resulted in the delivery of two female infants. The children have so far been followed for 3.5 and 7 years. The physical examination of both children was unremarkable. However, the older child has recently been diagnosed with attention deficit hyperactivity disorder and dyslexia.
authors.affiliation: University Hospital, Dutch-Speaking Free University of Brussels, AZ-VUB, Centre for Reproductive Medicine, Laarbeeklaaan 101, 1090 Jette, Brussels, Belgium. Evangelos.Papanikolaou@vub.ac.be
authors.forename: Evangelos G
authors.initials: EG
authors.lastname: Papanikolaou
authors.forename: Peter
authors.initials: P
authors.lastname: Platteau
authors.forename: Carola
authors.initials: C
authors.lastname: Albano
authors.forename: Efstratios
authors.initials: E
authors.lastname: Kolibianakis
authors.forename: Paul
authors.initials: P
authors.lastname: Devroey
mesh_terms: D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000209:etiology; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy*; D008183:Luteal Phase; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012449:Safety
chemical_list: D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin